BioAegis and Prenosis partner for inflammatory disease therapies

Pharmaceutical Business Review

The collaboration will evaluate biomarkers and patient subgroups with improved responses to BioAegis’ gelsolin therapy, a critical immune regulatory protein that aims to rebalance inflammation without

M&A / DealsImmunology & InflammationRead full story